Pfizer's GLP-1 drug showed 12% weight loss over six months with just one monthly injection. Experts say it could be years ...
1don MSN
Pfizer’s new weight-loss shot: Can one injection a month change obesity treatment as we know it?
With promising mid-stage trial results, berobenatide aims to make obesity treatment more convenient without compromising ...
By Michael Erman NEW YORK, June 6 (Reuters) - Pfizer presented data on Saturday that showed a monthly dose of an experimental ...
Nausea and vomiting rates for the monthly injectable berobenatide came in close to benchmarks set by Novo Nordisk's weekly ...
Pfizer presents positive results from multiple phase 2b studies of GLP-1 RA, berobenatide at 86th Scientific Sessions of ADA: New York Tuesday, June 9, 2026, 13:00 Hrs [IST] Pfize ...
Pfizer's experimental drug, berobenatide, is designed to stay attached longer to a blood protein called albumin, helping prevent it from breaking down too quickly.
Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF’3944), an ...
An oral drug from Pfizer causes a similar amount of weight loss as the blockbuster Ozempic injection, made by rival Novo Nordisk, according to results from a phase two clinical trial. The results were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results